Tahoe Therapeutics

Tahoe Therapeutics is a biotechnology company focused on the discovery and development of novel therapies targeting long non-coding RNAs (lncRNAs), often referred to as the "dark matter" of the genome. Incubated by Versant Ventures at its Ridgeline Discovery Engine in Basel, the company leverages cutting-edge genomic research to identify lncRNAs that play critical roles in disease progression, particularly in oncology. By utilizing a proprietary platform to map and modulate these regulatory RNA molecules, Tahoe Therapeutics aims to develop a new class of precision medicines for hard-to-treat cancers. The company's approach combines deep expertise in RNA biology with advanced drug discovery capabilities to translate academic breakthroughs into clinical candidates.